CGNNT(000881)2025-01-17 11:35Financial Performance - The company expects a net loss of between 29 million yuan and 42 million yuan for the year 2024, compared to a net loss of 73.72 million yuan in the same period last year[2]. - The net profit after deducting non-recurring gains and losses is projected to be a loss between 45 million yuan and 64 million yuan, down from a loss of 96.06 million yuan in the previous year[2]. - The basic earnings per share are expected to be a loss between 0.3067 yuan and 0.4442 yuan, compared to a loss of 0.7797 yuan per share last year[2]. Strategic Focus - The company is focusing on its "A+" strategy, with steady progress in operational management, innovation, and reform efforts, particularly in the accelerator and healthcare sectors[4]. - Significant investments are being made in the development and promotion of healthcare, nuclear environmental protection, and silicon photonics businesses, which are currently incurring losses[4]. Market Conditions - The company is experiencing pressure on product prices and gross margins due to industry cycle adjustments and intensified market competition in the new materials business[4]. Asset Management - The company plans to conduct comprehensive asset inspections and impairment tests, with provisions for potential asset impairments[5]. - The preliminary financial data is subject to change, and the final figures will be disclosed in the 2024 annual report[6].